An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT04866381
Phase
PHASE2
Status
Unknown

Conditions

  • Esophageal Squamous Cell Carcinoma
  • Progression to PD-1 Antibody

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is being conducted to explore the efficacy of SHR-6390 and SHR-1020 in the treatment of esophageal squamous cell carcinoma after progression on PD-1 Antibody.

Key Dates

First listed
Apr 29, 2021
Start date
Apr 30, 2021
Status verified
Apr 2021
Primary completion
Apr 30, 2023
Completion
Apr 30, 2023

Study Design

Enrollment
87 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-6390
    SHR-6390
  • Experimental: SHR-6390 combined with Camrelizumab (SHR-1210)
    SHR-6390 combined with Camrelizumab (SHR-1210)
  • Experimental: Camrelizumab (SHR-1210) combined with SHR-1020
    Camrelizumab (SHR-1210) combined with SHR-1020

Primary Outcome Measure

Objective Response Rate [ Time Frame: 1 year ]

Related Studies